IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) has filed a final short form prospectus in connection with its previously announced offering of a minimum of $5-million and a maximum of $10-million principal amount of 8%...
IntelGenx (OTCQX:IGXT; TSXV:IGX;) has received a notice of allowance from the U.S. Patent and Trademark Office for a patent application entitled, “Solid oral film dosage forms and methods for making same.” The platform...
Ladenburg Thalmann initiated coverage of Catalyst Biosciences (NASDAQ:CBIO) with a ‘buy” rating and $11.00 price target. The stock closed at $4.17 on June 5.
H.C. Wainwright initiated coverage of ZIOPHARM Oncology (NASDAQ:ZIOP) with a “buy” rating and $9.50 price target. The stock closed at $5.85 on May 31. Anchored by two cutting-edge technologies, ZIOPHARM is focused on...
Leerink upgraded Achillion Pharmaceuticals (NASDAQ:ACHN) to “outperform” from “market perform” and raised its price target to $6 from $4. The stock closed at $3.78 on May 17. Achillion has a portfolio of direct...
Quidel (NASDAQ:QDEL) has acquired the InflammaDry and AdenoPlus diagnostic businesses from RPS Diagnostics for about $14-million. InflammaDry is the only point-of-care test that detects elevated levels of MMP-9, a key...
Profound Medical (TSXV:PRN; OTCQX:PRFMF) posted revenue for the first time in the first quarter this year and reported that its TACT clinical trial to support a marketing application to the FDA for its TULSA-PRO device...
BTIG upgraded T2 Biosystems (NASDAQ:TTOO) to “neutral” from “sell,” saying the shares have fallen below a prior $4 price target. The stock closed at $3.98 on May 5. “While there is no change to our thesis on T2Candida...
Theratechnologies’ (TSX:TH) partner, TaiMed Biologics of Taiwan, completed the submission of a biologics license application (BLA) to the FDA for ibalizumab for the treatment of multidrug-resistant human...
Leerink downgraded Intra-Cellular Therapies (NASDAQ:ITCI) to “market perform” from “outperform” and slashed its price target to $10 from $29, following a corporate update highlighting an unusual preclinical safety...